Status:
COMPLETED
Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis
Lead Sponsor:
Jan Lycke
Conditions:
Multiple Sclerosis, Pharmacokinetics
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Serum and cerebrospinal fluid will be obtained from 20 patients with relapsing-remitting multiple sclerosis treated with teriflunomide tablets 14 mg daily
Detailed Description
Teriflunomide concentration in cerebrospinal fluid and serum will be determined in 12 patients with multiple sclerosis. They have been treated for at least 6 months and the sampling from blood and by ...
Eligibility Criteria
Inclusion
- patients with multiple sclerosis treated with teriflunomide 14 mg for at least 6 months
Exclusion
- other immunosuppressive or immunomodulating drugs, other CNS diseases
Key Trial Info
Start Date :
October 10 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2021
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04129736
Start Date
October 10 2019
End Date
June 30 2021
Last Update
December 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MS Centre
Gothenburg, Västra Götaland County, Sweden, 41345